Patrick John Finn Sells 2,207 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,207 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total transaction of $124,960.34. Following the completion of the sale, the chief operating officer now directly owns 171,212 shares in the company, valued at approximately $9,694,023.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, July 2nd, Patrick John Finn sold 476 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $22,848.00.
• On Friday, May 3rd, Patrick John Finn sold 2,311 shares of Twist Bioscience stock. The stock was sold at an average price of $37.13, for a total transaction of $85,807.43.

Twist Bioscience Price Performance

TWST traded up $1.25 during trading on Thursday, hitting $57.30. 768,702 shares of the stock traded hands, compared to its average volume of 1,029,384. The firm has a market capitalization of $3.34 billion, a P/E ratio of -17.05 and a beta of 1.80. The firm has a 50-day moving average of $49.14 and a 200 day moving average of $40.47. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $60.36.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.05. The business had revenue of $75.30 million during the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.06) EPS. As a group, equities analysts predict that Twist Bioscience Co. will post -3.08 EPS for the current fiscal year.

Analyst Ratings Changes

TWST has been the topic of a number of analyst reports. TD Cowen upped their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Evercore ISI boosted their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Robert W. Baird boosted their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. The Goldman Sachs Group boosted their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Finally, Barclays boosted their price target on shares of Twist Bioscience from $45.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, June 28th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $49.75.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TWST. EdgeRock Capital LLC bought a new position in Twist Bioscience in the 4th quarter worth $30,000. Blue Trust Inc. raised its holdings in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after acquiring an additional 546 shares in the last quarter. CWM LLC increased its stake in shares of Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after acquiring an additional 524 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Twist Bioscience in the 1st quarter worth about $124,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.